Results 41 to 50 of about 2,105 (152)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Frontiers in Immunology
IntroductionAntibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated in real-world clinical settings ...
Heng Chen, Gefei He, Juanjuan Huang, Lin Hu, Junlong Ma   +4 more
doaj   +1 more source

Self‐Immolative Systems in Diagnostic and Therapeutic Applications

ChemMedChem, Volume 21, Issue 5, 13 March 2026.
Self‐Immolative Systems enable the precise, residue‐free release of active molecules, drugs, probes, or sensors, via cyclization or elimination, triggered by specific stimuli. Their versatility drives advances in drug delivery, diagnostics, nanotechnology, materials chemistry, and biosensing, offering chemists control over molecular activation and ...
Windbedema Prisca Ouédraogo, Thomas Cailly, Valérie Collot   +2 more
wiley   +1 more source

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source

Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports

IJU Case Reports
Introduction Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end‐stage renal disease requiring hemodialysis.
Shintaro Mori, Tomohiro Matsuo, Hiroyuki Honda, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura   +7 more
doaj   +1 more source

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

Cancer Management and Research, 2020
Rohit K Jain, William Paul Skelton IV, Jingsong Zhang Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Jingsong ZhangDepartment of Genitourinary Oncology, H.
Jain RK, Skelton WP IV, Zhang J
doaj  

Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody–drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial
Deema Sabtan, Marie‐Lisa Eich, Florian Loch, Julen Karl Pérez Zuschneid, Markus Möbs, Judith Böhme, Frederick Klauschen, David Horst, Mihnea P Dragomir, Gabriel Dernbach, Simon Schallenberg   +10 more
wiley   +1 more source

Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system

Scientific Reports
Antibody–drug conjugates (ADCs) are among the fastest-growing classes of anticancer drugs, making it crucial to evaluate their potential for causing peripheral neuropathy. We analyzed data from the FAERS database (January 1, 2014, to June 30, 2023) using
Yuheng Chen, Xiayang Ren, Yuanyuan Dai, Yanfeng Wang   +3 more
doaj   +1 more source

Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma

Current Oncology
Antibody–drug conjugates (ADCs) have reshaped the treatment landscape of urothelial carcinoma (UC) by enabling selective delivery of highly potent cytotoxic agents to tumor cells.
Jing Huang, Ademola Ojo, Bobby Liaw
doaj   +1 more source

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates

Clinical and Translational Medicine, 2023
Introduction Antibody‐drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications. Material and methods In this article, we performed a deep analysis of their clinical landscape matched with ...
Cristina Nieto‐Jiménez, Adrián Sanvicente, Cristina Díaz‐Tejeiro, Víctor Moreno, Alfonso lopez deSá, Emiliano Calvo, Joaquín Martínez‐López, Pedro Pérez‐Segura, Alberto Ocaña   +8 more
doaj   +1 more source

Multi‐omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
We developed three UC clusters, applicable for MIBC and NMIBC, which were validated using transcriptomic- and proteomic datasets. Publically available UC cell lines were assigned to the clusters, to have in vitro models representing each cluster. The clusters differ in molecular and biological signatures, with distinct prognostic and therapeutic ...
Nils C. H. van Creij, Piotr Tymoszuk, Florian Handle, Andreas Seeber, Teresa Sellemond, Agnieszka Martowicz, Eva Comperat, Hamed Wafa, Steffen Ormanns, Michael Günther, Walther Parson, Maxim Noeparast, Frédéric R. Santer, José Daniel Subiela, Petros Grivas, Roger Li, Zoran Culig, Renate Pichler   +17 more
wiley   +1 more source